PDL BioPharma Inc  

(Public, NASDAQ:PDLI)   Watch this stock  
Find more results for pdli
8.49
+0.01 (0.12%)
Real-time:   11:47AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.40 - 8.55
52 week 7.38 - 10.20
Open 8.50
Vol / Avg. 860,247.00/3.64M
Mkt cap 1.36B
P/E 5.01
Div/yield 0.15/7.07
EPS 1.69
Shares 160.35M
Beta 0.40
Inst. own 86%
May 28, 2014
PDL BioPharma Annual Shareholder Meeting - 1:00PM EDT - Add to calendar
May 7, 2014
Q1 2014 PDL BioPharma Earnings Release (Tentative) - 4:00PM EDT - Add to calendar
Mar 5, 2014
PDL BioPharma at Cowen Health Care Conference
Mar 3, 2014
Q4 2013 PDL BioPharma Earnings Conference Call
Mar 3, 2014
Q4 2013 PDL BioPharma Earnings Release
Feb 26, 2014
PDL BioPharma at RBC Capital Markets Healthcare Conference
Feb 11, 2014
PDL BioPharma at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 55.47% 59.72%
Operating margin 87.75% 92.01%
EBITD margin - 93.28%
Return on average assets 50.34% 64.21%
Return on average equity 294.56% 1166.18%
Employees 8 -
CDP Score - -

Address

932 Southwood Blvd
INCLINE VILLAGE, NV 89451
United States - Map
+1-775-8328500 (Phone)
+1-775-8328501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

PDL BioPharma, Inc. (PDL) is a is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The Company receives royalties based on sales of humanized antibody products marketed and may also receive royalty payments on additional humanized antibody products launched before final expiry in December 2014. It has entered into licensing agreements with numerous entities that are independently developing or have developed humanized antibodies under which it has licensed certain rights under its Queen et al. patents to make, use, sell, offer for sale and import humanized antibodies.

Officers and directors

John P. McLaughlin President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Peter S. Garcia Chief Financial Officer, Vice President
Bio & Compensation  - Reuters
David Montez CPA Chief Accounting Officer, Controller
Age: 40
Bio & Compensation  - Reuters
Christopher Lewis Stone J.D. Vice President, General Counsel, Secretary
Age: 48
Bio & Compensation  - Reuters
Danny Hart Deputy General Counsel, Assistant Secretary
Age: 37
Bio & Compensation  - Reuters
David W. Gryska Director
Age: 57
Bio & Compensation  - Reuters
Jody S. Lindell Independent Director
Age: 62
Bio & Compensation  - Reuters
Paul W. Sandman Independent Director
Age: 65
Bio & Compensation  - Reuters
Harold E. Selick Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters